Clinical Trials Logo

Myeloid Metaplasia clinical trials

View clinical trials related to Myeloid Metaplasia.

Filter by:
  • None
  • Page 1

NCT ID: NCT00807677 Completed - Multiple Myeloma Clinical Trials

A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies

Start date: March 2009
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the maximum tolerated dose (MTD) of TAK-901 in subjects with advanced hematological malignancies, and to further assess the safety and tolerability of TAK-901 at or below the MTD in an expanded cohort of subjects in order to select a dose for future studies.

NCT ID: NCT00463385 Completed - Myelofibrosis Clinical Trials

A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia

Start date: April 1, 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety of and to select a treatment regimen of pomalidomide (CC-4047) either as single-agent or in combination with prednisone to study further in patients with myelofibrosis with myeloid metaplasia (MMM).

NCT ID: NCT00287261 Completed - Myelofibrosis Clinical Trials

A Trial of Zoledronic Acid in Patients With Myelofibrosis With Myeloid Metaplasia (MMM)

Start date: February 2006
Phase: Phase 2
Study type: Interventional

In this trial, the question is addressed if zoledronic acid (Zometa, Novartis Pharma)could be of clinical benefit for patients with myelofibrosis and myeloid metaplasia (MMM).

NCT ID: NCT00136409 Completed - Clinical trials for Chronic Myelomonocytic Leukemia

A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)

Start date: May 2002
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the effects (good and bad) of Gleevec in patients with BCR-negative myeloproliferative disorders including myelofibrosis with myeloid metaplasia and chronic myelomonocytic leukemia.

NCT ID: NCT00086125 Completed - Lymphoma Clinical Trials

Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)

Start date: June 2004
Phase: Phase 2
Study type: Interventional

The purpose of this phase II study is to assess the efficacy of AP23573 in patients with specified relapsed or refractory hematological malignancies.